ABVX:NASDAQ
Abivax SA
၉၁.၇၃ US$
arrow_downward
-၁.၂၄%(-၁.၁၅) 1D
၉၂.၁၆ US$
arrow_upward
+၀.၄၇% (+၀.၄၃)todayPre-market
Closed: အောက် ၅, GMT-၄ ၁၆:၀၀:၀၂ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
၉၂.၂၇ US$
High
၉၂.၆၁ US$
Low
၈၉.၄၀ US$
Mkt. cap
၇၁၈.၆၂ ဋေ
Avg. vol.
၁.၂၅ သန်း
Volume
၅.၆၆ ထောင်
52-wk high
၁၄၈.၈၃ US$
52-wk low
၆၉.၈၁ US$
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Open
၉၂.၂၇ US$
High
၉၂.၆၁ US$
Low
၈၉.၄၀ US$
Mkt. cap
၇၁၈.၆၂ ဋေ
Avg. vol.
၁.၂၅ သန်း
Volume
၅.၆၆ ထောင်
52-wk high
၁၄၈.၈၃ US$
52-wk low
၆၉.၈၁ US$
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Stock Traders Daily
·
ပြီးခဲ့သည့် ၇ နာရီ
(ABVX) as a Liquidity Pulse for Institutional Tactics
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com